Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Rebif

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Rebif was produced by Merck KGaA.

2015 set to be a transitional year for Merck KGaA's health unit

2015 set to be a transitional year for Merck KGaA's health unit down sales of its injectable multiple sclerosis (MS) drug Rebif (interferon beta-1a). ... Rebif sales fell nearly 16% to 430m as the MS market continues to switch towards oral therapies such as Biogen Idec's Tecfidera (dimethyl glutamate) and Novartis'

Sanofi persuades FDA to back its MS drug Lemtrada

Sanofi persuades FDA to back its MS drug Lemtrada Merck Serono's Rebif (interferon beta-1a). ... Lemtrada demonstrated superior efficacy over Rebif on annualised relapse rates in the two studies which were the basis for approval.”.

FDA approves Biogen Idec's long-acting MS therapy

FDA approves Biogen Idec's long-acting MS therapy The new long-acting formulation will give Biogen Idec a competitive advantage over interferon rivals such as Bayer's Betaferon/Betaseron (interferon beta-1b) and Merck Serono/Pfizer's Rebif (interferon

Rebif hit again as competition bites

Rebif hit again as competition bites Sales of Merck Serono's flagship multiple sclerosis drug Rebif (interferon beta-1a) were once again dragged down by fierce competition in the second quarter of 2014. ... Rebif's figures include negative exchange rate effects, and Merck insists that

Plegridy approval underlines Biogen Idec's dominance in MS

Plegridy approval underlines Biogen Idec's dominance in MS Plegridy's dosing gives Biogen Idec a competitive advantage over Avonex rivals such as Bayer's Betaferon/Betaseron (interferon beta-1b) and Merck Serono/Pfizer's Rebif (interferon beta-1a), and

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...